EW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EW

Mkt Cap

$49.90B

Volume

2.80M

Next Earnings

October 29th

Loading chart

EW

EWEdwards Lifesciences Corp

EW

Pay with—

Available Balance0.00

EW

Mkt Cap

$50.78B

Volume

2.80M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.Zacks Investment Research · Oct 7, 2026

Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.Zacks Investment Research · Sep 1, 2026

TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement SystemTRiCares has enrolled the first patient in its TRICURE US IDE pivotal study for the Topaz tricuspid valve replacement system, marking the first randomized controlled trial comparing an investigational TTVR device against Edwards' commercially available EVOQUE system. The global study will involve up to 75 sites across the US, Canada, and Europe, with the goal of demonstrating safety and effectiveness for treating severe tricuspid regurgitation.GlobeNewswire Inc. · Jul 9, 2026

Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve DeviceThe Centers for Medicare & Medicaid Services (CMS) proposed removing coverage with evidence development (CED) requirements for Transcatheter Aortic Valve Replacement (TAVR) in symptomatic severe aortic stenosis patients and expanding coverage to asymptomatic cases under CED. Edwards Lifesciences, which holds the only FDA-approved TAVR device for asymptomatic severe aortic stenosis, stands to gain a competitive advantage from these proposed changes. The stock rose 3.74% to $88.65 following the announcement.Benzinga · Jun 16, 2026

Edwards Lifesciences Stock Surges On Heart Valve Devices GrowthEdwards Lifesciences reported strong Q1 2026 earnings, beating consensus on both earnings (78 cents vs. 73 cents) and sales ($1.65B vs. $1.59B). The company saw 16.7% year-over-year sales growth driven by robust demand for heart valve therapies, particularly in TAVR and transcatheter mitral/tricuspid procedures. The company raised its 2026 EPS guidance and widened sales guidance, though Q2 guidance came in slightly below consensus. EW shares surged 4.58% to $83.37.Benzinga · Apr 24, 2026

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC FilingORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data to determine if the valuation is justified.The Motley Fool · Feb 20, 2026

Pulmonary Artery Catheter Market Size to Reach USD 1.97 Billion by 2035 Caused by the Surging Critical Care Procedures GloballyThe global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.GlobeNewswire Inc. · Feb 17, 2026

Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate ThrombectomyBoston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.Benzinga · Jan 15, 2026

Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValveA U.S. District Court granted the FTC's motion to block Edwards Lifesciences' $1.2 billion acquisition of JenaValve Technology, citing concerns that the deal would eliminate competition in the TAVR-AR device market and potentially harm innovation and patient access. Despite the setback, Edwards raised its 2026 adjusted EPS guidance to $2.90-$3.05 and continues advancing its own transcatheter aortic regurgitation valve.Benzinga · Jan 12, 2026

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS InsiderThe global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.GlobeNewswire Inc. · Jan 12, 2026

to start trading

EW

EWEdwards Lifesciences Corp

EW

Pay with—

Available Balance0.00

Your PositionYou don't own any EW yet.

Related Tickers

Earnings